- Trials with a EudraCT protocol (30)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
30 result(s) found for: covid-19 AND placebo AND vaccine.
Displaying page 2 of 2.
«
Previous
1
2
EudraCT Number: 2020-001483-28 | Sponsor Protocol Number: VAC31518COV1001 | Start Date*: 2020-07-14 |
Sponsor Name:Janssen Vaccines & Prevention B.V. | ||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 1/2a Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26COVS1 in Adults Aged 18 to 55 Years Inclusive and Adults Aged 65 Ye... | ||
Medical condition: Healthy volunteers (Prevention of COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005989-34 | Sponsor Protocol Number: 034B20 | Start Date*: 2022-08-31 | |||||||||||
Sponsor Name:Aphaia Pharma AG | |||||||||||||
Full Title: A Phase II, randomized, double-blind, placebo-controlled, parallel-group proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese s... | |||||||||||||
Medical condition: Obesity with/without associated endocrine and/or metabolic conditions and/or hypertension and/or NASH and/or NAFL with/without fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003205-29 | Sponsor Protocol Number: CAP2022-1 | Start Date*: 2023-02-23 | |||||||||||
Sponsor Name:Aphaia Pharma US LLC | |||||||||||||
Full Title: A Phase II, randomized, placebo – controlled crossover proof-of-concept study to evaluate efficacy and safety of distal jejunal-release dextrose beads formulation (APHD-012) in subjects with a path... | |||||||||||||
Medical condition: Subjects with a pathological Oral Glucose Tolerance Test (OGTT) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005444-35 | Sponsor Protocol Number: C4591015 | Start Date*: 2021-04-15 | |||||||||||
Sponsor Name:BioNTech SE | |||||||||||||
Full Title: A PHASE 2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID-19 IN HEAL... | |||||||||||||
Medical condition: Protection against COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: In utero, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005276-14 | Sponsor Protocol Number: RGCH004 | Start Date*: 2016-06-03 | |||||||||||
Sponsor Name:Sykehuset Østfold HF | |||||||||||||
Full Title: Prolonging the response by low-dose Rituximab maintenance therapy in immune thrombocytopenia: a randomized placebo-controlled trial- the PROLONG trial. | |||||||||||||
Medical condition: Immune thrombocytopenia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) DK (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000665-32 | Sponsor Protocol Number: 80202135SJS2001 | Start Date*: 2021-11-12 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Ongoing) IT (Completed) PL (Completed) PT (Completed) NL (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003302-50 | Sponsor Protocol Number: ARGX-117-2002 | Start Date*: 2022-01-31 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicit... | |||||||||||||
Medical condition: Multifocal Motor Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed) PL (Completed) AT (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002571-18 | Sponsor Protocol Number: 170KG18 | Start Date*: 2019-07-22 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: EFFECT OF FERRIC CARBOXYMALTOSE ON EXERCISE CAPACITY AFTER KIDNEY TRANSPLANTATION: A MULTICENTER RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Iron deficiency in kidney transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003234-37 | Sponsor Protocol Number: 80202135CDP3001 | Start Date*: 2022-08-23 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Phase 2/3, Multistage, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chron... | |||||||||||||
Medical condition: Chronic Inflammatory Demyelinating Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) CZ (Trial now transitioned) FR (Trial now transitioned) SK (Prematurely Ended) DE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000169-42 | Sponsor Protocol Number: KPL-404-C211 | Start Date*: 2022-10-28 | |||||||||||
Sponsor Name:Kiniksa Pharmaceuticals, Ltd. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Subjects with Moderate to Severe, Active Rheumatoid Art... | |||||||||||||
Medical condition: Rheumatoid arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
«
Previous
1
2
